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The virological and cellular consequences of persistent hepatitis C virus (HCV) infection have been elusive
due to the absence of the requisite experimental systems. Here, we report the establishment and the charac-
teristics of persistent in vitro infection of human hepatoma-derived cells by a recently described HCV genotype
2a infectious molecular clone. Persistent in vitro infection was characterized by the selection of viral variants
that displayed accelerated expansion kinetics, higher peak titers, and increased buoyant densities. Sequencing
analysis revealed the selection of a single adaptive mutation in the HCV E2 envelope protein that was largely
responsible for the variant phenotype. In parallel, as the virus became more aggressive, cells that were resistant
to infection emerged, displaying escape mechanisms operative at the level of viral entry, HCV RNA replication,
or both. Collectively, these results reveal the existence of coevolutionary events during persistent HCV infection
that favor survival of both virus and host.
The hepatitis C virus (HCV) is a hepatotropic, positive-
stranded RNA virus that causes acute and chronic hepatitis.
Because most infections become persistent, HCV chroni-
cally infects more than 170 million people worldwide, many
of whom will develop liver cirrhosis and hepatocellular car-
cinoma (15). HCV is thought to be noncytopathic in vivo,
and the pathogenesis of the associated hepatitis is assumed
to reﬂect destruction of HCV infected cells by cytotoxic
CD8
 T cells (9).
HCV is the sole member of the genus Hepacivirus in the
Flaviviridae family. Its 9.6-kb RNA genome encodes a long
open reading frame that is co- and posttranslationally cleaved
by cellular and viral proteases into structural (core, E1, E2, and
p7) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and
NS5B) proteins (2). The viral life cycle and the host-virus
interactions that determine the outcome of HCV infection
have been difﬁcult to study due to the absence of a tissue
culture model of HCV infection. Recently, several groups (16,
20, 25, 29, 31) have developed cell culture models of HCV
infection that release HCV particles that are infectious for
human hepatoma-derived cell lines. The most robust of these
in vitro infections are based on the extraordinary replicative
capacity of the genotype 2a JFH-1 strain of HCV, which rep-
licates efﬁciently in vitro without requiring adaptive mutations
(14). Importantly, cell culture-derived JFH-1 and a chimeric
virus expressing the structural region of the related J6 strain of
HCV and the nonstructural region of JFH-1 are infectious for
chimpanzees and uPA-SCID mice reconstituted with human
hepatocytes (17, 25).
At present, the cell culture system has been used primarily to
study the early steps of HCV infection. For example, we and
others (16, 31) have reported that primary HCV infection can
be inhibited by blocking the interaction between the HCV E2
glycoprotein and the cellular protein CD81, an important co-
receptor for HCV entry (3, 13, 18, 30). In the current study, we
used the cell culture system to elucidate the virological and
cellular consequences of persistent HCV infection. Here, we
demonstrate that HCV can establish persistent infection in
vitro for at least 6 months and that it can induce cytopathic
effects when expressed at high levels, which lead to the selec-
tion of viral and host variants that favor the survival of both.
The viral evasion and host survival mechanisms illustrated in
this report may provide insights into the pathophysiology of
chronic HCV infection and, possibly, other persistent RNA
virus infections as well.
MATERIALS AND METHODS
Cell culture, molecular cloning, in vitro transcription, and HCV RNA trans-
fection. The cell culture condition and protocols for in vitro transcription and
HCV RNA electroporation have been described previously (31). Individual viral
mutations were introduced into the pJFH-1 plasmid (25) by two-step recombi-
nant PCR using primers containing the mutation, followed by restriction diges-
tion and ligation (protocols are available upon request). All constructs were
veriﬁed by DNA sequencing.
RNA analysis, indirect immunoﬂuorescence, and titration of infectious HCV.
RNA Isolation and quantitative reverse transcription-PCR (RT-QPCR) analysis
of intracellular HCV RNA were performed as previously described (31). The
CD81 mRNA levels were measured by RT-QPCR with the primers 5-CACTG
ACTGCTTTGACCACC-3 and 5-CACCATGCTCAGGATCATCTC-3 and
normalized to cellular GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
levels. Intracellular staining was performed as previously described, using poly-
clonal anti-NS5A rabbit antibody MS5 (31). Titration assays were performed as
previously described using Huh-7.5.1 cells (31).
HCV infection kinetics assay. Eighty thousand Huh-7.5.1 cells were seeded in
12-well plates overnight and then inoculated with HCV at the multiplicity of
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 infection (MOI) indicated in the ﬁgure legends. The infected cells reached
conﬂuence on day 4 postinfection and were then split at a ratio of 1:3 into 12-well
plates (harvested on day 6), 6-well plates (harvested on day 8 or 9), and T25
ﬂasks (harvested on day 10 or at later time points). No split was necessary after
day 10 due to cytopathic effects of the infection. Culture supernatants were
collected at the indicated time points, and infectivity titers were determined by
titrating on Huh-7.5.1 cells.
Sedimentation equilibrium gradient analysis. Gradients were formed by over-
laying 700 l of 20%, 30%, 40%, 50%, and 60% sucrose solutions in TNE buffer
(10 mM Tris-HCl [pH 8], 150 mM NaCl, 2 mM EDTA). Approximately 250 to
500 l of viral supernatants with infectivity titers of 10
4 focus-forming units
(FFU)/ml were overlaid on the gradients. Equilibrium was reached by ultracen-
trifugation (SW41Ti rotor; Beckman Instruments, Palo Alto, CA) for 16 h at
120,000  g at 4°C. Fifteen fractions of 250 l were collected from the top and
analyzed for virus infectivity titers as described above. The density of each
fraction was determined by measuring the mass of 100-l aliquots in each
sample.
HCV RNA genome sequencing. HCV RNA was isolated from 0.3 ml of viral
supernatants with infectivity titers between 10
3 and 10
5 FFU/ml by the guanidine
thiocyanate method (27) and then used as a template to generate cDNA in a
reverse transcription reaction, followed by two rounds of nested PCR. The
protocols for reverse transcription and nested PCR and the primer sequences
were provided by J. Bukh (unpublished data).
Blockade of HCV infection by CD81 antibody. Ten thousand Huh-7.5.1 cells
were pretreated with 0, 0.1, 0.25, 1, 2.5, and 25 g/ml of CD81 antibody (clone
5A6; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h and then infected with
50 focus-forming units of the wild-type or G451R mutant viruses for5hi na
96-well plate. The viruses were removed, and the cells were washed with phos-
phate-buffered saline and then supplemented with complete medium. The efﬁ-
ciency of the infection was monitored 3 days later by quantitating the number of
HCV-positive foci by immunoﬂuorescence as described above.
Isolation of HCV-negative cells by serial dilution. Persistently infected R1, R2,
and Huh-7 cells, which are designated Huh-7/scr cells in this report, were serially
diluted and plated in 96-well plates. The smallest number of seeded cells that can
survive in one well of a 96-well plate is 15 to 150. After 2 to 3 weeks of culture,
wells with the lowest seeding densities were screened for the presence of infec-
tious HCV in the culture supernatants by the titration assay. The cells with
HCV-negative supernatants were expanded, examined for HCV NS5A protein
by immunoﬂuorescent microscopy, and conﬁrmed to be HCV RNA negative by
RT-QPCR.
CD81 transfection. Plasmid pEE6-hCD81, which expresses human CD81 (12),
was transfected into R1, R2, and R3 cells by using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA), following the manufacturer’s protocol. The cells were
seeded in a 6-well plate overnight and were 80 to 90% conﬂuent at the time of
transfection. Following transfection, the cells were incubated at 37°C for 18 h and
then plated in a 12-well plate (7  10
4 cells per well) and a T25 ﬂask (7  10
5
cells per ﬂask). On day 2 posttransfection, the cells in the T25 ﬂask were
collected for CD81 cell surface staining and ﬂuorescence-activated cell sorter
(FACS) analysis. At the same time, the cells in the 12-well plate were inoculated
with HCV at an MOI of 0.1. The cells were harvested for RNA extraction on day
3 postinfection and analyzed by RT-QPCR for intracellular-HCV-RNA levels.
Flow cytometric analysis of CD81 and SR-BI expression on the cell surface.
Approximately 0.3 to 1  10
6 cells were resuspended in 100 l of staining buffer
(1% fetal calf serum–phosphate-buffered saline) and incubated for1ho ni c e
with a monoclonal mouse anti-human CD81 antibody (Serotec, Raleigh, NC) or
a polyclonal rabbit anti-SR-BI antibody (Novus Biologicals, Littleton, CO) at a
1:100 dilution. After being washed, the cells were incubated in 100 l of staining
buffer for 30 min on ice with phycoerythrin-conjugated anti-mouse immunoglob-
ulin G1 (BD/Pharmingen, San Diego, CA) or anti-rabbit immunoglobulin G
(Santa Cruz Biotechnology) at a 1:200 dilution. Cells stained with the respective
secondary antibody alone served as negative controls. FACS analysis was per-
formed using the FACSArray Bioanalyzer system (BD Bioscience, San Jose, CA).
HCVpp genesis and infection. HCV pseudotyped retroviral particles (HCVpp)
were generated as previously described (13). Brieﬂy, using Lipofectamine, 293T
cells were cotransfected with the envelope-deﬁcient human immunodeﬁciency
virus genome pNL4-3.Luc.R-.E- and a plasmid expressing any of the following
viral glycoproteins: HCV strain H (genotype 1a), H77 (1a), OH8 (1b), or Con1
(1b); murine leukemia virus (MLV) env; or an empty vector (mock). The me-
dium was replaced with Dulbecco’s modiﬁed Eagle’s medium with 3% fetal
bovine serum after 6 h. Supernatants were collected after 48 h and clariﬁed by
centrifugation. For infection experiments, supernatants were diluted in Dulbec-
co’s modiﬁed Eagle’s medium with 3% fetal bovine serum and incubated with
cells for 7 h prior to removal and incubation for a further 72 h. Cells were lysed
with 40 l cell culture lysis reagent (Promega, Madison, WI), and infection was
measured by quantifying the expression of the luciferase reporter using 50Jl
luciferase substrate (Promega) and a Centro LB960 luminometer (Berthold
Technologies, Bad Wildbad, Germany).
HCV replicon RNA transfection. One microgram of in vitro-transcribed HCV
genotype 1b subgenomic replicon RNA (S1179I) containing a neo marker (7)
was electroporated into R1, R2, and R3 cells and their parental Huh-7.5.1 and
Huh-7/scr cells, following the electroporation protocol as previously described
(31). After electroporation, one-third of the cells were plated in a 10-cm dish.
G418 (300 g/ml) was added 1 day after transfection and was refreshed every 4
to 5 days. G418-resistant colonies were stained with crystal violet 3 weeks after
transfection.
RESULTS
Persistent HCV infection in cell culture. To determine
whether JFH-1 virus can establish a persistent infection in cell
culture, we electroporated JFH-1 genomic RNA into Huh-7/
scr and Huh-7.5.1 cells and cultured the transfected cells for up
to 6 months. At the indicated time points (normally when the
cells were nearly conﬂuent and ready to split), the culture
supernatants were assessed for infectious virus, the intracellu-
lar-HCV-RNA levels, and the frequency of viral-antigen-
NS5A-positive cells. In two independent experiments trans-
fecting Huh-7.5.1 cells (denoted Exp 1 and Exp 2) (Fig. 1A and
B), intracellular-HCV-RNA levels decreased signiﬁcantly dur-
ing the ﬁrst few days following transfection and then re-
bounded, reaching maximal levels (2  10
7 genome equiva-
lents [GE] per g cellular RNA) by day 18 posttransfection.
Similarly, the levels of infectious extracellular virus reached a
peak (10
4 to 10
5 FFU per ml) by day 18 posttransfection, when
the majority of cells in the culture expressed NS5A. Interest-
ingly, as illustrated in Fig. S1 in the supplemental material, cell
growth rate was greatly reduced and many cells became
rounded and ﬂoated in the culture medium by day 18 post-
transfection, when levels of HCV RNA, antigen, and secreted
infectious virus were maximal. The cytopathic effects lasted
approximately 2 weeks, after which the cells recovered. Unex-
pectedly, following the recovery of the levels of intracellular
HCV RNA, those of extracellular infectious virus and NS5A-
positive cells declined and ﬂuctuated during the following 6
months, indicating the establishment of a dynamic persistent
infection. During this period of persistent infection, the cells
were cytologically normal although occasionally very minor
cytopathic effects were observed.
Transfection of JFH-1 genomic RNA into Huh-7/scr cells
(denoted Exp 3) (Fig. 1C) showed similar infection kinetics,
although the initial expansion was delayed and the amount of
secreted infectious virus reduced, reaching a peak of 6  10
3
FFU/ml by day 26 posttransfection. In contrast to what was
found for Huh-7.5.1 cells, minimal cytopathic effects were ob-
served in Huh-7 cells at the peak of JFH-1 infection (Fig. S1 in
the supplemental material). Nonetheless, as with Huh-7.5.1
cells, the amounts of secreted infectious virus and intracellular
HCV RNA and the frequency of NS5A-positive cells de-
creased signiﬁcantly after reaching peak levels and ﬂuctuated
widely thereafter for at least 6 months (Fig. 1C).
In subsequent experiments, we established persistent HCV
infections in Huh-7.5.1 (Fig. S2 in the supplemental material)
and Huh-7/scr (not shown) cells by inoculating them with virus
produced in the transfection experiments described above.
These persistent infections displayed the same characteristics
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 as those described above, indicating that persistence is inde-
pendent of the process used to initiate the infection.
Collectively, these results indicate that HCV can persistently
infect Huh-7.5.1 and Huh-7/scr cells in vitro, HCV infects the
majority of cells within the population at the peak of infection,
HCV can induce variable cytopathology, and the surviving cells
show ﬂuctuating levels of viral replication and secretion of
infectious virus over a 6-month period. For the convenience of
discussion, we deﬁne the acute phase of infection as the time
following primary virus infection, leading to a peak of extra-
cellular-infectious-virus levels, followed by a period of cytopathol-
ogy, leading to a trough of viral replication. The chronic phase of
infection is deﬁned as the events that transpire thereafter.
Enhancement of HCV infectivity during persistent infection.
Although the levels of extracellular infectious virus and intra-
cellular viral RNA ﬂuctuate considerably during the chronic
phase of Exp 1, the levels of extracellular infectious virus
regularly returned to the initial day-18 peak while the intracel-
lular RNA content did not. Furthermore, the frequency of
NS5A-positive cells during the chronic phase was always below
50% (often below 1%), compared to nearly 100% at the peak
of the acute phase. (Fig. 1A). These results suggest that either
more virus particles are produced per intracellular RNA mol-
ecule or the secreted virus particles are more infectious. To
investigate these two possibilities, we collected the extracellu-
lar virus from Exp 1 on days 18, 119, 155, and 183 posttrans-
fection and examined their ability to expand in naı ¨ve Huh-7.5.1
cells after inoculation at an MOI of 0.002. As illustrated in Fig.
2A, the chronic-phase (days 119, 155, and 183) virus titers
increased more rapidly than the acute-phase (day 18) virus
titers (Fig. 2A). In keeping with these ﬁndings, the intracellu-
lar-HCV-RNA levels also increased more rapidly in the chronic-
phase-virus-infected cells (data not shown). In addition, the
chronic-phase viruses produced higher peak infectivity titers
(10
5 to 10
6 FFU/ml) than the acute-phase viruses (1.6  10
4
FFU/ml). We repeated the infection kinetics assay by using
FIG. 1. Persistent HCV infection in Huh-7.5.1 and Huh-7/scr cells. Cells were transfected with 10 g JFH-1 RNA and maintained in culture
for 6 months. Infectious-viral titers in the culture supernatants (red diamonds, left y axis) and intracellular-HCV-RNA levels (black open
diamonds, right y axis) were measured by the titration assay and RT-QPCR and are expressed as numbers of FFU/ml and GE/g cellular RNA,
respectively. NS5A immunostaining of transfected cells at the selected time points is shown in the right-hand panels. NS5A is red (Alexa 555), and
nuclei are blue (Hoechst). The scale bar represents 100 M. The asterisks represent the time points (days 18, 119, 155, and 183 of Exp 1, days 18
and 160 of Exp 2, and days 26 and 99 of Exp 3) at which we collected viruses for the infection kinetics assays whose results are shown in Fig. 2.
11084 ZHONG ET AL. J. VIROL.
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 progeny of day 18 and day 183 viruses, both of which were
collected on day 8 postinfection in the infection experiment
described in the legend to Fig. 2A. As shown in Fig. 2C, the
progeny of the day 183 virus expanded more rapidly and
reached a higher titer than the progeny of day 18 virus, sug-
gesting that the enhanced infectivity is likely due to changes in
the genomes of chronic-phase viruses. This notion was further
conﬁrmed by transfecting chronic-phase-viral-RNA genomes
into naı ¨ve Huh-7.5.1 cells and then monitoring the viral-expan-
sion kinetics (Document S2 in the supplemental material).
FIG. 2. Viral evolution during persistent infection. (A and B) Kinetics of viral production after infection with acute- and chronic-phase viruses.
Huh-7.5.1 cells were inoculated at an MOI of 0.002, with viral supernatants collected on day 18, 119, 155, or 183 posttransfection in Exp 1 (A) or
on day 18 or 160 posttransfection in Exp 2 (B). The supernatants were harvested at the indicated time points after infection and the infectivity titers
determined. (C) Kinetics of viral production after infection with progeny of acute- and chronic-phase viruses. Huh-7.5.1 cells were inoculated at
an MOI of 0.004 with progeny of day 18 and day 183 viruses (Exp 1) and day 18 and day 160 viruses (Exp 2). The supernatants were harvested
at the indicated time points after infection and the infectivity titers determined. (D and E) Buoyant densities of acute- and chronic-phase viruses.
The viruses collected at days 18, 119, and 183 posttransfection in Exp 1 (D) and the viruses collected at day 18 and day 160 posttransfection in
Exp 2 (E) were analyzed in a 20 to 60% sucrose gradient. The infectivity titer for each fraction was determined, and the density of each fraction
was determined by measuring the mass of a 100-l aliquot of the fraction. The infectivity titer for each fraction is expressed as the percentage of
the total titer for all fractions.
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 To determine whether the chronic-phase viruses from Exp 2
and Exp 3 also acquired enhanced infectivities, we inoculated
naı ¨ve Huh-7.5.1 cells with viruses collected on days 18 and 160
posttransfection in Exp 2 and on days 26 and 99 posttransfec-
tion in Exp 3 and monitored the viral-expansion kinetics as
described above. As shown in Fig. 2B, the day 160 virus from
Exp 2 displayed more-rapid kinetics and reached a higher titer
than the day 18 virus. Moreover, the enhanced infectivities of
this virus could be passed to its progeny (Fig. 2C). In contrast,
the kinetics and maximal titer displayed by the chronic-phase
virus (day 99) from Exp 3 were comparable to those displayed
by the acute-phase virus (day 26) in that experiment (data not
shown).
The buoyant densities of viral particles change during per-
sistent infection. To compare the biophysical properties of the
viral particles produced during the acute and chronic phases of
infection, we analyzed the buoyant densities of day 18 virus
with those of day 119 and day 183 viruses from Exp 1 by
sucrose density gradient ultracentrifugation analysis. As shown
in Fig. 2D, the buoyant densities of the day 18 virus were
distributed over a broad range (between 1.03 and 1.16 g/ml),
whereas the lowest-density fractions of the day 119 and 183
viruses contained minimal infectivities, resulting in a rightward
shift in the mean density of the virus. Importantly, progeny of
chronic-phase viruses displayed a similar buoyant-density
change (data not shown), suggesting that genetic changes in
the chronic-phase viral genome are responsible for this phe-
notype. We also analyzed the buoyant densities of chronic-
phase viruses in Exp 2 and Exp 3. As shown in Fig. 2E, chronic-
phase virus (day 160) from Exp 2 displayed a similar density
change, while the density proﬁle for day 99 virus from Exp 3
was similar to that for the acute-phase virus (data not shown).
Identiﬁcation of genetic mutations in chronic-phase virus.
To identify the genetic changes that are responsible for the
observed phenotypic changes in the chronic-phase viruses, we
sequenced the RNA genomes of viruses collected on days 18,
59, 119, 155, and 183 posttransfection in Exp 1. There were no
mutations in the day 18 virus, but mutations were identiﬁed in
the chronic-phase viruses. As shown in Fig. 3, four mutations
appeared in the day 59 virus (K74T in core, G451R in E2,
M1051T in NS3, and C2219R in NS5A) and became ﬁxed and
maintained in viruses isolated on days 119, 155, and 183 post-
transfection, implying that they were all present in the majority
of viral genomes at those time points. The appearance of these
mutations was associated with the appearance of enhanced
infectivity and the changed density proﬁles.
To determine whether these mutations were responsible for
the enhanced infectivities and altered densities of the chronic-
phase virus, we engineered each mutation individually into the
JFH-1 genome. The in vitro-transcribed recombinant JFH-1
RNA was electroporated into Huh-7.5.1 cells, and the ability of
the resultant viruses to expand in naı ¨ve Huh-7.5.1 cells was
examined. As shown in Fig. 4A, the G451R (E2) virus ex-
panded more rapidly and reached higher titers than the wild
type and other mutant viruses, suggesting that the G451R
mutation in E2 is responsible for enhanced infectivity. We also
noted that the G451R mutant virus displayed an accelerated
cytopathic effect compared to the wild-type virus (data not
shown). Furthermore, sucrose density analysis indicated that
the buoyant densities of the G451R virus were similar to those
of the chronic-phase viruses, while the densities of the other
mutant viruses were similar to those of wild-type JFH-1 virus
(Fig. 4A). These results suggest that the mutation in the viral-
envelope glycoprotein E2 is primarily responsible for both the
enhanced infectivities and the density changes seen in chronic-
phase viruses.
The increased level of infectious virus obtained from chron-
ically infected cultures may result from an increase in the
absolute number of particles secreted or an increased propor-
tion of infectious particles relative to noninfectious particles.
To address this question, we compared the speciﬁc infectivities
of mutant viruses and those of viruses collected from different
phases of infection and determined the ratio of viral infectivity
titer (FFU/ml) to HCV RNA (GE/ml) content. As shown in
Fig. 4B, the chronic-phase (D183) and G451R (E2) viruses had
higher speciﬁc-infectivity titers (1:294 and 1:312, respectively)
than acute-phase and other single-point-mutant viruses (be-
tween 1:2,240 and 1:5,320), suggesting that particles released
from long-term chronically infected cultures are more infec-
tious, and the glycine-to-arginine substitution at position 451 in
E2 appears to be responsible for the altered speciﬁc infectivi-
ties.
To illuminate the mechanism of action of the G451R muta-
tion, we compared the infection of Huh-7.5.1 cells by the wild-
type and G451 mutant viruses in the presence of increasing
concentrations of CD81 antibody. As shown in Fig. 4C, al-
though the CD81 antibody could block the infection by both
the wild-type and the G451R mutant viruses, it appears that
the infection by the mutant virus is less dependent upon the
cell surface CD81 molecules than the infection by the wild-type
virus, suggesting that the G451R mutation may confer a selec-
tive advantage to the mutant virus at the entry level.
FIG. 3. Genetic mutations identiﬁed during persistent infection. A schematic diagram of the JFH-1 open reading frame is shown on the top.
The numbers for the amino acid positions where mutations were identiﬁed in Exp 1 are marked with asterisks.
11086 ZHONG ET AL. J. VIROL.
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 Emergence of HCV-resistant cells during persistent infec-
tion. As shown in Fig. 1, the intracellular-HCV-RNA levels
and frequency of NS5A-positive cells during the chronic phase
of infection are lower than those seen at the peak of the acute
phase, despite the increased infectivities of the chronic-phase
viruses (Fig. 2). Indeed, as shown in Fig. S4A in the supple-
mental material, as few as 2% of the persistently infected cells
were NS5A positive on day 85 posttransfection in Exp 1. None-
theless, the virus produced by those cells was able to infect
more than 60% of naı ¨ve Huh-7.5.1 cells within 3 days of inoc-
ulation (Fig. S4B in the supplemental material), raising the
possibility that some cells within the persistently infected cell
culture are resistant to HCV infection. To test this hypothesis,
we inoculated persistently infected Huh-7.5.1 cells from Exp 2
with viruses collected from Exp 1. As shown in Fig. S5 in the
supplemental material, although naı ¨ve Huh-7.5.1 cells were
efﬁciently infected by HCV (more than 80% NS5A-positive
cells on day 9 postinfection), the persistently infected cells
appeared resistant to secondary infection.
One explanation for this resistance is that HCV is present
within all cells of the persistently infected culture beneath the
level of detection of NS5A immunoﬂuorescence. In this case,
secondary HCV infection could be inhibited by previously ac-
tivated host antiviral mechanisms or by competition for host
cell resources. To examine these possibilities, we isolated
NS5A-negative cells from Exp 1 (on day 119), Exp 2 (on day
72), and Exp 3 (on day 160) by serial dilution and demon-
strated the cells to be free of HCV RNA by RT-QPCR analysis
(3  10
5 GE per cell). These cells were named R1, R2, and
R3 cells, respectively. To determine whether these HCV-neg-
ative cells could be infected by JFH-1, they were inoculated,
along with parental Huh-7.5.1 and Huh-7/scr cells, with HCV
(day 18 of Exp 2) at an MOI of 0.05. Cells were stained for
NS5A protein 3 days later. As shown in Fig. 5A, 80% of
Huh-7.5.1 (Fig. 5A, panel I) and 50% of Huh-7/scr (Fig. 5A,
panel V) cells were NS5A positive, while 0.06% of R1 (Fig. 5A,
panel II), 1% of R2 (Fig. 5A, panel III), and 0.01% of R3
(Fig. 5A, panel VI) cells were NS5A positive at this time point.
In parallel experiments, we demonstrated that the R1, R2, and
R3 cells were resistant to HCV from different sources, includ-
FIG. 4. The G451R mutation in E2 is responsible for the enhanced
infectivities and altered buoyant densities of chronic-phase virus.
(A) Infection kinetics and buoyant densities of mutant viruses. Top:
Huh-7.5.1 cells were inoculated at an MOI of 0.004 with mutant JFH-1
viruses, and the supernatants were harvested at the indicated time
points after infection and the infectivity titers determined. Bottom:
mutant viruses were subjected to a 20 to 60% sucrose gradient, and the
infectivity titer for each fraction was determined. The density of each
fraction was determined by measuring the mass of a 100-l aliquot of
the fraction and is the average for four gradients. WT, wild type. (B)
Speciﬁc-infectivity titers for acute- and chronic-phase virus (progeny of
day 18 and 183 viruses in Exp 1) and mutant JFH-1 viruses. The
wild-type and mutant viruses were prepared from the same experi-
ment. Each speciﬁc-infectivity titer is the average for two measure-
ments. (C) Blockade of HCV infection by CD81 antibody. The Huh-
7.5.1 cells were pretreated with 0, 0.1, 0.25, 1, 2.5, and 25 g/ml of
CD81 antibody (clone 5A6) for 1 h and then infected with 50 focus-
forming units of the wild-type or G451R mutant viruses for 3 days. The
infection was monitored by HCV immunoﬂuorescence, and the num-
bers of HCV-positive foci were counted. Each result is expressed as a
fraction of the number of foci observed in wells that received medium
instead of anti-CD81. The error bars represent the standard deviations
for four replicates.
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 ing day 18 (MOI, 0.05) and day 183 (MOI, 0.15) viruses from
Exp 1; day 160 (MOI, 0.15) virus from Exp 2; and day 26 (MOI,
0.05) virus from Exp 3 (data not shown).
To demonstrate that the low frequency of NS5A-postive
cells on day 3 postinfection was not merely a reﬂection of
delayed infection kinetics in these cells, we monitored the
intracellular-HCV-RNA levels for 13 days following infection.
As shown in Fig. 5B, the intracellular-HCV-RNA levels in R1
and R3 cells decreased to 10
2 to 10
3 GE per g cellular RNA
on day 13 postinfection, at which point no NS5A-positive cells
were detected by immunoﬂuorescence (data not shown). In
contrast, R2 cells appeared more susceptible to HCV infection
than R1 and R3 cells, but JFH-1 infection was impaired rela-
tive to parental Huh-7.5.1 cells (Fig. 5B). Importantly, the
intracellular-HCV-RNA levels in R2 cells failed to increase
signiﬁcantly even by 13 days postinfection, and the frequency
of NS5A-postive cells was approximately 2% by 14 days postin-
fection (Fig. 5A, panel IV). Taken together, these results sug-
gest that host cells evolve during persistent infection to become
resistant to HCV infection.
Loss of cellular CD81 expression during persistent infec-
tion. To elucidate the mechanism(s) for resistance to HCV
infection, we compared the cell surface expression of the viral
coreceptor CD81 on parental Huh-7 and Huh-7.5.1 cells with
that on R1, R2, and R3 cells by ﬂow cytometry. CD81 cell
surface expression levels on R3 and R1 cells were greatly
FIG. 5. The emergence of HCV-resistant cells during persistent infection. (A) NS5A staining of naı ¨ve Huh-7.5.1 (I), R1 (II), R2 (III), Huh-7/scr
(V), and R3 (VI) cells that were infected with HCV at an MOI of 0.05 for 3 days and NS5A-staining of R2 (IV) cells that were infected with HCV
at an MOI of 0.01 for 14 days. The estimated frequency for NS5A-positive cells is indicated on the bottom of each image. For all images, NS5A
staining is in red (Alexa 555), and nuclei were stained with Hoechst (blue). The white scale bars represent 100 M. (B) R1, R2, R3, and their
parental Huh-7.5.1 and Huh-7/scr cells were infected with acute-phase HCV (day 18 in Exp 1) at an MOI of 0.01. The cells were harvested at the
indicated time points after infection, and the intracellular-HCV-RNA levels were determined by RT-QPCR and normalized to cellular GAPDH
levels.
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 reduced compared to those on their respective parental pop-
ulations (Fig. 6A and Fig. S7 in the supplemental material),
and these observations were conﬁrmed at the CD81 mRNA
level by RT-QPCR (data not shown). In contrast, R2 cells
showed relatively normal CD81 expression levels, although the
intensity of CD81 staining was slightly reduced compared to
that for the parental cells (Fig. 6A). We also examined cell
surface expression levels of scavenger receptor class B type I
FIG. 6. Loss of CD81 expression in persistently infected cells. (A) CD81 cell surface staining of R1, R2, R3, and their parental Huh-7.5.1 and
Huh-7/scr cells. The cells were stained with a mouse anti-human CD81 antibody followed by a phycoerythrin-conjugated secondary antibody.
(B) Intracellular-HCV-RNA levels in the CD81-transfected R1, R2, and R3 cells 3 days after infection. Cells were transfected with 80 ng, 400 ng,
and 2 g of the CD81 expression plasmid (pEE6-hCD81) or 2 g pCDNA3 plasmid. At 48 h posttransfection, the cells were infected with HCV
(day 18 of Exp 1) at an MOI of 0.1. The intracellular-HCV-RNA levels were analyzed by quantitative RT-PCR, normalized to the cellular GAPDH
levels, and expressed as the percentages of the intracellular-HCV-RNA levels in the corresponding parental cells. The error bars represent the
standard deviations for three measurements. (C) Infection of parental Huh-7.5.1, Huh-7/scr, and resistant R1, R2, and R3 cells, before and after
transduction with lentiviral vectors expressing CD81 and the related tetraspanin CD9, with HCVpp bearing H77, OH8, Con1, and J6 glycoproteins.
Results are expressed as numbers of relative light units (RLU) normalized based on a control MLV pseudotyped-retroviral-particle infection. (D,
E, and F) CD81 mRNA levels during the entire course of persistent infection in Exp 1 (D), Exp 2 (E), and Exp 3 (F). CD81 mRNA levels were
measured by RT-QPCR and normalized to cellular GAPDH levels.
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 (SR-BI), an additional viral coreceptor (3, 23, 24). SR-B1 was
expressed at similar levels in the resistant and parental cells
(data not shown).
To conﬁrm that the reduced susceptibilities of R1 and R3
cells to JFH-1 infection is due to the lack of CD81 expression,
we transfected increasing amounts of a CD81 expression vec-
tor (12) into R1, R2, and R3 cells. On day 2 posttransfection,
we determined CD81 cell surface expression levels by ﬂow
cytometry and infected transfected cells with JFH-1 at an MOI
of 0.1. As shown in Fig. S6 in the supplemental material,
transfection of CD81-expressing plasmids restored CD81 cell
surface expression in R1 and R3 cells in a dose-dependent
manner, while CD81 cell surface expression levels in R2 cells
remained unchanged. More importantly, R3 cells transfected
with the CD81 plasmid could be efﬁciently infected by JFH-1,
with maximal CD81 expression restoring the infection to levels
seen in the parental Huh-7/scr cells (Fig. 6B). CD81 expression
in R1 cells rescued JFH-1 infection, albeit less efﬁciently than
that in R3 cells. In contrast, the susceptibility of R2 cells to
JFH-1 infection remained unchanged after CD81 transfection,
suggesting that the defect(s) in R2 cells is independent of
CD81 expression.
To conﬁrm that the block to infection of R1 and R3 cells was
at the level of viral entry, we infected these cells with
pseudotyped lentiviruses bearing diverse HCV envelope glyco-
proteins E1 and E2 (HCVpp) (H77, OH8, Con1, and J6). As
shown in Fig. 6C, the R1 and R3 cells were resistant to HCVpp
infection while the parental Huh-7.5.1 and Huh-7/scr cells and
the R2 cells were susceptible to infection. Transduction of cells
to express CD81, but not CD9, a negative control, restored
CD81 cell surface expression in R1 and R3 cells (Fig. S7 in the
supplemental material) and their ability to support HCVpp
infection (Fig. 6C). Collectively, these results illustrate that the
resistance to HCV infection observed in R1 and R3 cells is due
to the absence of CD81 expression in these cells.
To determine when the CD81-negative cells emerged during
the persistent infection, we analyzed CD81 mRNA levels
throughout the course of infection in Exp 1, Exp 2, and Exp 3
(Fig. 6D, E, and F). As expected, we observed a signiﬁcant
decrease in CD81 mRNA levels during persistent infection
in Exp 1 and Exp 3 prior to the time when the R1 (day 119)
and R3 (day 160) cells were derived, respectively. CD81
mRNA levels decreased between days 69 and 85 posttrans-
fection in Exp 1 and between days 26 and 54 posttransfec-
tion in Exp 3. Interestingly, CD81 expression levels also
decreased between days 77 and 116 posttransfection in Exp
2, but this decrease occurred after the CD81-positive R2
cells were isolated (day 72).
Inhibition of HCV RNA replication during persistent infec-
tion. The aforementioned results demonstrate that R2 cells are
relatively resistant to HCV infection despite expressing CD81
and supporting HCVpp entry. In addition, CD81 transfection
of R1 cells only partially rescued infection by JFH-1 but could
fully restore HCVpp entry (Fig. 6B and C). These results
suggest that R1 and R2 cells have an additional defect(s)
downstream from viral entry. To test this possibility, we exam-
ined the abilities of these cells to support HCV replicon rep-
lication. As shown in Fig. 7, R3 cells were able to support HCV
replicon replication as efﬁciently as naı ¨ve Huh-7 cells, whereas
the abilities of R1 and R2 cells to support replicon replication
were greatly reduced, suggesting that inefﬁcient HCV RNA
replication in R1 and R2 cells likely contributed to the resis-
tance to JFH-1 infection.
To assess whether the resistance to HCV infection observed
in R1, R2, and R3 cells extended to other viruses, we inocu-
lated them and the parental Huh-7.5.1 and Huh-7/scr cells with
vesicular stomatitis virus. Our results indicated that the HCV-
resistant cells were as susceptible to vesicular stomatitis virus
infection as their parental cell lines (data not shown).
DISCUSSION
Using a recently established system to propagate infectious
HCV based on a genotype 2a JFH-1 strain of HCV (25, 31), we
report that JFH-1 can persistently infect Huh-7/scr and Huh-
7.5.1 cells for periods of 6 months or more. The system is
characterized by a variable cytopathic effect at the peak of
acute infection and by ﬂuctuating levels of extracellular infec-
tious virus, intracellular HCV RNA, and HCV-infected cells
during the persistent phase of infection. Interestingly, both the
virus and the host cell evolve during persistent infection, with
the virus acquiring increased speciﬁc infectivity and the host
cells becoming resistant to HCV infection.
FIG. 7. R1 and R2 cells do not support HCV replicon replication
efﬁciently. One microgram of genotype 1b subgenomic replicon
(S1179I) was electroporated into 4  10
6 Huh-7/scr, R3, Huh-7.5.1,
R1, and R2 cells. One-third of the cells were plated on a 10-cm dish
and subjected to 300 g/ml G418 selection for 3 weeks. The colonies
were ﬁxed and stained with crystal violet.
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 HCV infection can be cytopathic in vitro. HCV has long
been regarded as a noncytopathic virus. The destruction of
hepatocytes during HCV-associated hepatitis is believed to be
the result of cytotoxic-T-cell-mediated clearance of HCV-in-
fected hepatocytes. Interestingly, we observed that, in the ab-
sence of an adaptive immune response, JFH-1 can induce
cytopathic effects in Huh-7.5.1 cells and, to a lesser degree, in
the Huh-7 cells. The molecular basis for this observation is not
clear; however, the cytopathic potential of the JFH-1 clone
may reﬂect the fact that it is based on the consensus sequence
of a genotype 2a virus that was isolated from a patient with
acute fulminant hepatitis, an extremely rare event. It is worth
noting that infection of chimpanzees with JFH-1 or J6/JFH
failed to induce fulminant hepatitis; however, the levels of
replication observed in the infected animals were low (17, 25).
Since the magnitude of the cytopathic effect is greater in the
RIG-I-deﬁcient Huh-7.5.1 cells than in Huh-7/scr cells, cellular
factors may also contribute to the cytopathic effect. Additional
studies will be necessary to understand the pathophysiological
basis for these different outcomes.
Virus evolution during persistent infection. Mutation of gly-
cine to arginine at amino acid (a.a.) 451 in E2 is primarily
responsible for the more rapid viral-expansion kinetics, higher
infectious titers, increased speciﬁc infectivities, and buoyant-
density changes observed in viruses that evolved in Exp 1. The
increased speciﬁc infectivities of the E2 mutant virus suggests
that this mutation allows more-efﬁcient production of infec-
tious viral particles. The infection by the G451R mutant virus
appears to be less dependent upon the CD81 molecules on the
cell surface than that by the wild-type virus, which gives the
virus a selective advantage during the late period of persistent
infection when the CD81-deﬁcient cells emerge. The glycine at
position 451 is located between hypervariable region 1 (a.a. 384
to 410) and hypervariable region 2 (a.a. 474 to 482) within the
N terminus of E2 (28), a region that has been reported to
modulate the accessibility of the CD81 binding site (22). This
residue appears to be conserved, since BLAST analysis of 502
HCV sequences in the NCBI database yielded only one se-
quence (BAA03375) encoding an arginine at this position as
seen with the chronic-phase virus from Exp 1. It will be inter-
esting to observe the kinetics, magnitude, and severity of in-
fection of a G451R mutant virus in vivo.
In addition to the change in E2, mutations in core (K74T),
NS3 (M1051T), and NS5A (C2219R) were selected for chronic-
phase viruses in Exp 1. Recombinant viruses containing
these mutations were produced by transfecting in vitro-tran-
scribed RNA into Huh-7.5.1 cells, suggesting that the wild-type
amino acids at these positions are not essential for virus via-
bility. Interestingly, we did not detect signiﬁcant differences in
the viral-expansion kinetics and buoyant-density proﬁles be-
tween the mutant and wild-type viruses. Given that these mu-
tations were selected during persistent infection, they may fa-
vor HCV survival and/or expansion in ways that remain to be
determined.
Although chronic-phase virus (day 160) from Exp 2 dis-
played more-rapid expansion kinetics and altered buoyant den-
sities, it does not contain the G451R mutation. Nonetheless,
other mutations were observed in this isolate, including V22A
and K74Q in core and V388P, I414T, and L644I in E2. It is
possible that one or more of these mutations could be respon-
sible for the phenotype of the day 160 virus, and this hypothesis
is currently under investigation. Interestingly, the chronic-
phase virus from Exp 3 did not show enhanced infectivities or
changes in buoyant density as observed in viruses from Exp 1
and Exp 2. One possible explanation is that the intracellular-
HCV-RNA levels are lower in the persistently infected Huh-
7/scr cells (Exp 3) than in Huh-7.5.1 cells (Exp 1 and Exp 2),
thereby reducing opportunities for random mutations.
Interestingly, we observed a change in the buoyant densities
of the chronic-phase viruses from Exp 1 and Exp 2. Such a
density change for HCV is not unusual in vivo. It has been
reported that the densities of HCV isolated from chronic hep-
atitis patients are higher than those of acute virus (21, 26),
although it was suggested that the higher densities reﬂect the
presence of virus-bound antibodies. Based on our current re-
sults, we speculate that the change in viral density occurring
during persistent infection in cell culture reﬂects changes in
the composition of virus-associated cellular proteins or the
lipid composition of the viral envelope, likely due to the mu-
tation in E2. Further investigation will be necessary to test
these hypotheses.
Host evolution during persistent infection. Another exciting
aspect of these results is the rapid emergence of cells that are
resistant to HCV infection and dominate the persistently in-
fected cell culture. HCV-free cells derived from three inde-
pendent persistent infections displayed resistance to JFH-1
infection. We do not know whether small numbers of resistant
cells were present in the parental Huh-7/scr and Huh-7.5.1 cell
lines or whether they emerged during HCV infection. In either
scenario, however, selective forces likely imposed by the virus
were responsible for the outgrowth and dominance of the
resistant cells. More experiments will be needed to identify the
basis for selection. The minor frequency of cells that support
HCV replication in the resistant cell lines may reﬂect the
heterogeneous nature of these cells, since the resistant cell
lines were not isolated from a single clone, or various CD81
expression levels, some of which are above a threshold level
required for HCV infection (A. Jennings and J. A. McKeating,
unpublished data).
Importantly, different mechanisms are responsible for resis-
tance to HCV infection in the three resistant cell lines ob-
tained. R3 cells lack CD81 cell surface expression, which ex-
plains their inability to support JFH-1 infection and HCVpp
entry. This defect can be fully complemented by CD81 trans-
fection or transduction, indicating that the lack of CD81 ex-
pression in R3 cells forms the basis for their resistance to
JFH-1 infection. In contrast, R2 cells express CD81 at a level
comparable to those for the parental cells and support HCVpp
entry but fail to support efﬁcient JFH-1 infection, suggesting a
defect downstream of viral entry, most likely at the level of
viral-RNA replication. Interestingly, R1 cells display defects in
both HCVpp entry and HCV RNA replication. Both defects
may be necessary for efﬁcient curing of viral infection since
initiation and spread of viral infection are efﬁciently inhibited
by blocking viral entry, while inhibition of viral-RNA replica-
tion is better suited for purging virus from existing infected
cells. Further experiments are needed to identify the molecular
basis of the defect(s) in HCV RNA replication in R1 and R2
cells.
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 Perspectives. The current observations illustrate several
general principles that may be relevant for the pathophysiology
of HCV and other persistent RNA viral infections. For exam-
ple, the evolution of cells that are resistant to HCV infection in
vitro raises the possibility that similar events may occur within
the persistently infected liver. Indeed, although it is difﬁcult to
quantify HCV-infected cells in vivo, Bigger and colleagues,
using quantitative HCV RNA analysis of liver RNA from
acutely (5) and chronically (6) HCV-infected chimpanzees,
estimated that between 0.1% and 30% of hepatocytes may be
infected at any point in time and that the extents of infection
may be limited by the relative magnitudes of the innate im-
mune responses elicited in different animals. While we agree
with this hypothesis, the results presented herein suggest that
other factors may also be operative. For example, hepatocytes
in the liver are a heterogeneous population of cells (13a) that
could display differential susceptibilities to HCV infection. As
a result, the constitutive resistance of a subset of hepatocytes to
HCV infection, coupled with immune elimination of HCV-
infected hepatocytes, may select for the repopulation of the
liver with resistant cells during persistent infection. Similarly,
viral variants with increased speciﬁc infectivities and relative
levels of ﬁtness for the environment of the persistently infected
liver may evolve. Of course, we would expect the time scale of
events in vivo to be much slower (requiring years, perhaps
decades) than that of events observed in vitro (occurring in
weeks) because of the differences in hepatocyte turnover rates
under in vivo and in vitro conditions. Indeed, these events
occur at a much slower pace in a new in vitro HCV infection
model that we have recently developed using dimethyl sulfoxide-
treated Huh-7/scr cells that are more highly differentiated than
the rapidly dividing Huh-7/scr cells used in the current exper-
iments and display growth arrest when becoming conﬂuent
(22a). Nonetheless, the principles illustrated in our in vitro
experiments may provide new insights into the pathophysiol-
ogy of persistent HCV infection in vivo where hepatocyte
death and cell division are driven by the cytotoxic-T-cell re-
sponse (9). Future experiments to extend these observations to
other viral strains and target cells, particularly primary human
hepatocytes, are clearly warranted. Finally, these results are
consistent with reports that similar events of virus and host cell
coevolution may contribute to the pathophysiology of persis-
tent reovirus (1, 11), rotavirus (19), coronavirus (8), and foot-
and-mouth disease virus (10) infections, illustrating the general
principle of coevolutionary selection and emphasizing its bio-
logical and clinical importance.
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